ABIONYX Pharma announced that the Company's Phase 2b RACERS study in sepsis has been selected as a late-breaking clinical trial poster presentation at the 2023 American Society of Nephrology Annual Meeting taking place November 2-5, 2023 in Philadelphia, Pennsylvania.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.024 EUR | +0.59% | -4.66% | -20.50% |
Mar. 14 | Abionyx Pharma: to benefit from a 1ME grant from Bpifrance | CF |
Mar. 11 | Abionyx: reduced net loss in 2023 | CF |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-20.50% | 35.21M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- ABNX Stock
- News ABIONYX Pharma
- ABIONYX Pharma RACERS Study in Sepsis Selected for Late-Breaking Clinical Results Poster Presentation at the American Society of Nephrology 2023 Annual Meeting " Kidney Week"